XML 51 R40.htm IDEA: XBRL DOCUMENT
v3.25.2

SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details) - USD ($) |  | 3 Months Ended | 6 Months Ended | 38 Months Ended |
--- | --- | --- | --- | --- | ---
Apr. 24, 2024 | Jun. 30, 2025 | Jun. 30, 2024 | Jun. 30, 2025 | Jun. 30, 2024 | Apr. 23, 2024 | Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Acquired in-process research and development |  | $ 0 | $ 84,883,000 | $ 0 | $ 84,883,000 |  |
Revenue from collaborative agreement |  | 0 | 302,000 | 0 | 1,275,000 |  |
Accounts receivable |  | 1,859,000 |  | 1,859,000 |  |  | $ 1,694,000
Janssen Pharmaceuticals, Inc. | Related Party | Collaborative Arrangement |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Payments related to collaborative agreement |  |  |  |  |  | $ 27,000,000 |
Collaborative agreement, maximum cost share |  |  |  |  |  | 47,800,000 |
Revenue from collaborative agreement |  |  | 302,000 |  | $ 1,275,000 |  |
Revenue, remaining performance obligation, amount |  | 0 |  | 0 |  |  |
Accounts receivable |  | $ 0 |  | $ 0 |  |  | $ 0
Janssen Pharmaceuticals, Inc. | License Agreement | Related Party | Collaborative Arrangement |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Payments related to collaborative agreement | $ 85,000,000 |  |  |  |  |  |
Milestone payment obligation, development and regulatory | 150,000,000 |  |  |  |  |  |
Milestone payment obligation, commercialization | 455,000,000 |  |  |  |  |  |
Acquired in-process research and development |  |  | 85,400,000 |  |  |  |
Direct transaction costs |  |  | $ 400,000 |  |  |  |
Janssen Pharmaceuticals, Inc. | License Agreement | Upfront Payment | Related Party | Collaborative Arrangement |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Acquired in-process research and development | $ 84,900,000 |  |  |  |  |  |
Contract liability |  |  |  |  |  | 500,000 |
Janssen Pharmaceuticals, Inc. | Milestone Achievement | Related Party | Collaborative Arrangement |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |
Revenue from collaborative agreement |  |  |  |  |  | $ 10,000,000 |

X
- Definition Collaborative Arrangement, Maximum Third Party Share Of Cost + References No definition available. + Details
Name: | cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Rights And Obligations, Milestone Payments, Commercialization + References No definition available. + Details
Name: | cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Rights And Obligations, Milestone Payments, Development And Regulatory + References No definition available. + Details
Name: | cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Direct Transaction Costs + References No definition available. + Details
Name: | cdtx_DirectTransactionCosts
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments Related To Collaborative Agreements + References No definition available. + Details
Name: | cdtx_PaymentsRelatedToCollaborativeAgreements
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research And Development Expense, Acquired In Process + References No definition available. + Details
Name: | cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability + References No definition available. + Details
Name: | cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3 + Details
Name: | us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=cdtx_UpfrontPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |